April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Vision Outcomes Following Cataract Surgery in Ranibizumab (LUCENTIS®) Treated Patients With Wet Age-Related Macular Degeneration in MARINA and ANCHOR Trials
Author Affiliations & Notes
  • P. J. Rosenfeld
    Bascom Palmer Eye Institute, Univ of Miami Miller Sch of Med, Miami, Florida
  • H. Shapiro
    Genentech, Inc., South San Francisco, California
  • L. Scott
    Genentech, Inc., South San Francisco, California
  • Footnotes
    Commercial Relationships  P.J. Rosenfeld, Genentech, F; Alcon, F; Quark/Pfizer, F; Othera, F; Potentia, F; CoMentis, F; Carl Zeiss Meditec, R; Othera, R; Neovista, R; Bausch&Lomb, R; Sanofi-Aventis, R; Oraya, R; H. Shapiro, Genentech, Inc., E; L. Scott, Genentech, Inc., E.
  • Footnotes
    Support  Genentech, Inc.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2362. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. J. Rosenfeld, H. Shapiro, L. Scott; Vision Outcomes Following Cataract Surgery in Ranibizumab (LUCENTIS®) Treated Patients With Wet Age-Related Macular Degeneration in MARINA and ANCHOR Trials. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2362.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : In the pivotal MARINA and ANCHOR trials of ranibizumab for neovascular (wet) age-related macular degeneration (AMD), ranibizumab-treated patients, on average, demonstrated improvement from baseline visual acuity (VA). During those trials, some patients underwent cataract surgery. We performed a retrospective analysis to explore whether cataract surgery was beneficial in wet AMD patients undergoing ranibizumab therapy.

Methods: : We analyzed eyes receiving ranibizumab (pooled 0.3 mg and 0.5 mg doses) of MARINA and ANCHOR patients who had cataract surgery. For this analysis, VA prior to cataract surgery was defined as baseline. Mean change from pre-surgery baseline VA, time to the first injection post surgery, number of injections post surgery, and mean follow-up time post surgery were assessed.

Results: : Of 758 pooled ranibizumab-treated patients, cataract surgery was performed on 23 eyes. Three months post surgery, mean (SEM) VA improved by 11.4 (3.3) letters in ranibizumab-treated eyes (n=21), with a 95% confidence interval ranging from +4.6 letters to +18.3 letters. The average time from the first ranibizumab treatment to the time of surgery was 431 days, following an average of 13.6 injections. The first post surgery injection of ranibizumab was performed, on average, 36 days after surgery.

Conclusions: : In MARINA and ANCHOR, cataract surgery resulted in greater than two lines of VA improvement and appeared to be beneficial for eyes undergoing ranibizumab therapy for neovascular AMD.

Keywords: age-related macular degeneration • choroid: neovascularization • cataract 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.